Integrating Multi-Biomarker Panels and Emerging Technologies in A Systematic Meta Analysis of Biomarkers for Early Sepsis Detection, Prognosis and Therapeutic Monitoring in Critically Ill Patients
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2025
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901551359983616 |
|---|---|
| author | Dr. Subashini R*, Grace S, Janani B S, Jayashree T, Gayathri M |
| author_facet | Dr. Subashini R*, Grace S, Janani B S, Jayashree T, Gayathri M |
| contents | <p><span>Current diagnostic and prognostic approaches focused on individual biomarkers and clinical scores are inadequate to fully capture the complex, varied pathobiology of sepsis, which continues to be a major cause of death globally. In addition to evaluating the effectiveness of integrated multi-biomarker panels for early identification, risk stratification, and treatment monitoring in critically ill patients, this systematic review and meta-analysis synthesize evidence on established and new sepsis biomarkers. While novel proteomic (presepsin, calprotectin), transcriptomic (miRNAs, lncRNAs, circRNAs), metabolomic, extracellular vesicle-based, and coagulation markers add complementary pathophysiologic dimensions, conventional markers such as procalcitonin, C-reactive protein, lactate, and organ-specific indices offer significant but incomplete information. Combinations of inflammatory, immunological, endothelial, coagulation, and metabolic biomarkers regularly show better sensitivity, specificity, AUC, and likelihood ratios than any single biomarker across diagnostic accuracy and prognostic meta-analyses. Multi-biomarker panels combined with advanced analytics (logistic regression, random forests, AI models) and clinical scores (SOFA, qSOFA, APACHE II) improve early sepsis detection, forecast organ failure and mortality, and enable dynamic treatment adaption, including antibiotic de-escalation. The translational potential of biomarker-guided treatment is further increased by concurrent developments in artificial intelligence, multi-omics integration, point-of-care diagnostics, digital wearables, and next-generation sequencing. Significant obstacles still exist, nevertheless, such as methodological heterogeneity, a lack of established cut-offs, restricted validation in a variety of groups, implementation difficulties, and limitations unique to a given technology. Precision methods offered by technology and multi-biomarkers have the potential to revolutionize sepsis treatment and enhance worldwide result.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17816585 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Integrating Multi-Biomarker Panels and Emerging Technologies in A Systematic Meta Analysis of Biomarkers for Early Sepsis Detection, Prognosis and Therapeutic Monitoring in Critically Ill Patients Dr. Subashini R*, Grace S, Janani B S, Jayashree T, Gayathri M Sepsis, Multi-biomarker panels, Procalcitonin, Inflammatory biomarkers, Systematic review and meta-analysis <p><span>Current diagnostic and prognostic approaches focused on individual biomarkers and clinical scores are inadequate to fully capture the complex, varied pathobiology of sepsis, which continues to be a major cause of death globally. In addition to evaluating the effectiveness of integrated multi-biomarker panels for early identification, risk stratification, and treatment monitoring in critically ill patients, this systematic review and meta-analysis synthesize evidence on established and new sepsis biomarkers. While novel proteomic (presepsin, calprotectin), transcriptomic (miRNAs, lncRNAs, circRNAs), metabolomic, extracellular vesicle-based, and coagulation markers add complementary pathophysiologic dimensions, conventional markers such as procalcitonin, C-reactive protein, lactate, and organ-specific indices offer significant but incomplete information. Combinations of inflammatory, immunological, endothelial, coagulation, and metabolic biomarkers regularly show better sensitivity, specificity, AUC, and likelihood ratios than any single biomarker across diagnostic accuracy and prognostic meta-analyses. Multi-biomarker panels combined with advanced analytics (logistic regression, random forests, AI models) and clinical scores (SOFA, qSOFA, APACHE II) improve early sepsis detection, forecast organ failure and mortality, and enable dynamic treatment adaption, including antibiotic de-escalation. The translational potential of biomarker-guided treatment is further increased by concurrent developments in artificial intelligence, multi-omics integration, point-of-care diagnostics, digital wearables, and next-generation sequencing. Significant obstacles still exist, nevertheless, such as methodological heterogeneity, a lack of established cut-offs, restricted validation in a variety of groups, implementation difficulties, and limitations unique to a given technology. Precision methods offered by technology and multi-biomarkers have the potential to revolutionize sepsis treatment and enhance worldwide result.</span></p> |
| title | Integrating Multi-Biomarker Panels and Emerging Technologies in A Systematic Meta Analysis of Biomarkers for Early Sepsis Detection, Prognosis and Therapeutic Monitoring in Critically Ill Patients |
| topic | Sepsis, Multi-biomarker panels, Procalcitonin, Inflammatory biomarkers, Systematic review and meta-analysis |
| url | https://doi.org/10.5281/zenodo.17816585 |